



## KVK Tech – Recall of atovaquone oral suspension

- On August 6, 2021, [KVK Tech announced](#) a voluntary, consumer-level recall of two lots of [atovaquone](#) oral suspension due to prolonged exposure to extremely cold weather during shipment.
- There were customer complaints of unusual grittiness in the product, which was probably caused by exposure to extremely low temperatures.

| Product Description                                     | NDC#         | Lot# (Expiration Date) |
|---|--------------|------------------------|
| Atovaquone oral suspension, 750 mg/5 mL<br>8 oz. bottle | 10702-223-21 | 16653A (12/2022)       |
|   |              | 16654A (12/2022)       |

- Atovaquone is indicated for the prevention and acute treatment of *Pneumocystis jiroveci* in adults and adolescents who cannot tolerate trimethoprim-sulfamethoxazole.
- Exposure of atovaquone oral suspension to extremely low temperatures, during shipment (the product is required to be protected from freezing temperatures), may result in changes to the effectiveness, appearance, taste and thickness of the liquid. Severely immunocompromised patients who receive less effective atovaquone may experience inadequate treatment of serious and life-threatening infections.
- To date, KVK Tech is not aware of any adverse events associated with this problem.
- Patients who have the recalled atovaquone should stop use and contact their pharmacy or KVK Tech for return and replacement information. Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled atovaquone.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact KVK Tech by phone **1-215-579-1842 (ext. 6002)** or by email at [recall@kvktech.com](mailto:recall@kvktech.com) for any questions related to the recall.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.